Therapeutic drug monitoring of kinase inhibitors in oncology
MBA van der Kleij, NAD Guchelaar… - Clinical …, 2023 - Springer
Although kinase inhibitors (KI) frequently portray large interpatient variability, a 'one size fits
all'regimen is still often used. In the meantime, relationships between exposure-response …
all'regimen is still often used. In the meantime, relationships between exposure-response …
Management of diarrhea induced by EGFR-TKIs in advanced lung adenocarcinoma
D Cárdenas-Fernández… - Therapeutic …, 2023 - journals.sagepub.com
The identification of Epidermal Growth Factor Receptor (EGFR) mutations in lung
adenocarcinoma has facilitated the development of personalized medicine based on …
adenocarcinoma has facilitated the development of personalized medicine based on …
Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small …
EBF Ebert, T McCulloch, KH Hansen, H Linnet… - Lung Cancer, 2020 - Elsevier
Objectives Epidermal growth factor receptor (EGFR) mutations confer sensitivity to tyrosine
kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). However, a subset of …
kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). However, a subset of …
The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon …
CJ Yang, MJ Tsai, JY Hung, MH Lee, YM Tsai… - BMC Pharmacology and …, 2017 - Springer
Background Afatinib is a second-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI). Compared to cytotoxic chemotherapy, afatinib has been …
tyrosine kinase inhibitor (TKI). Compared to cytotoxic chemotherapy, afatinib has been …
Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literature
A Fahmy, AM Hopkins, MJ Sorich… - Expert Opinion on Drug …, 2021 - Taylor & Francis
Introduction: Orally administered small molecule kinase inhibitors (KI) are a key class of
targeted anti-cancer medicines that have contributed substantially to improved survival …
targeted anti-cancer medicines that have contributed substantially to improved survival …
Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients
H Kenmotsu, CK Imamura, T Kawamura… - Cancer Chemotherapy …, 2022 - Springer
Purpose To evaluate the relationship between treatment efficacy and exposure of total and
unbound erlotinib in patients with non-small cell lung cancer (NSCLC) harboring epidermal …
unbound erlotinib in patients with non-small cell lung cancer (NSCLC) harboring epidermal …
Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy
A Sekine, H Satoh, T Iwasawa, K Tamura… - Medical oncology, 2014 - Springer
The aim of this study was to explore prognostic factors for non-small cell lung cancer
(NSCLC) patients with brain metastases (BM) on the basis of EGFR mutation status. Among …
(NSCLC) patients with brain metastases (BM) on the basis of EGFR mutation status. Among …
Optimized dosing: the next step in precision medicine in non-small-cell lung Cancer
In oncology, and especially in the treatment of non-small-cell lung cancer (NSCLC), dose
optimization is often a neglected part of precision medicine. Many drugs are still being …
optimization is often a neglected part of precision medicine. Many drugs are still being …
Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy
A Sekine, H Satoh - Medical Oncology, 2017 - Springer
Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)
mutations commonly present brain metastases (BM) at the time of NSCLC diagnosis or …
mutations commonly present brain metastases (BM) at the time of NSCLC diagnosis or …
Afatinib therapy for brain metastases aggravated by a reduction in the dose of erlotinib due to the development of hepatotoxicity
Y Yamanaka, A Sekine, T Kato, H Yamakawa… - Internal …, 2017 - jstage.jst.go.jp
We report an 80-year-old woman with EGFR-mutant lung adenocarcinoma with multiple
brain metastases (BMs). All lesions including BM showed a successful resolution after …
brain metastases (BMs). All lesions including BM showed a successful resolution after …